

Proligo Licensed to Manufacture and Market Oligos Labeled with Beckman Coulter WellRED Dyes

Proligo Licensed to Manufacture and Market Oligos Labeled with Beckman Coulter WellRED Dyes

BOULDER, Colorado (October 15th, 2002) – Proligo® and Beckman Coulter, Inc. announced today a worldwide supply and license agreement by which Proligo will manufacture and sell oligonucleotides labeled with Beckman Coulter WellRED Dyes, D2-PA, D3-PA, D4-PA. These new oligos will run on Beckman Coulter's CEQ™ Genetic Analysis Systems.

"We are delighted to enter into this relationship with Beckman Coulter," said Bruno Poddevin, Vice President, Proligo Primers & Probes. "Our worldwide manufacturing capabilities will ensure a timely and reliable supply of high-quality labeled oligos for Beckman Coulter's CEQ Systems customers across the globe.

"Proligo's knowledge of specialty oligo synthesis and worldwide manufacturing facilities makes them an ideal supplier for us," commented Keith Offord, vice president of Biological Systems Operations, Beckman Coulter. "With this agreement, we can expand the availability and application of WellRED dye-labeled custom oligos."

Proligo delivers innovative consumables to power functional genomics. Proligo's expertise spans the genomics development supply chain, from oligonucleotide synthesis reagents to production of oligonucleotides. A subsidiary of Degussa AG, Proligo is headquartered in Boulder, Colorado, USA and has manufacturing facilities in France, Germany, USA, Japan, Australia and Singapore.

Beckman Coulter, Inc. is a global biomedical company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing, and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled \$2 billion in 2001, with 62% of this amount generated by recurring revenue from supplies, test kits and services.